Ryvu Therapeutics SA (WAR:RVU) — Stock Price
Ryvu Therapeutics SA (WAR:RVU) is currently trading at zł15.72 PLN, up 0.90% today. Over the past 52 weeks, shares have ranged between zł13.76 and zł30.70. This page tracks Ryvu Therapeutics SA's live share price on the WAR exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Ryvu Therapeutics SA market capitalisation.
Ryvu Therapeutics SA (RVU) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Ryvu Therapeutics SA's daily closing share price and trading volume on the WAR exchange over the past year, giving a clear view of recent price momentum and liquidity.
Ryvu Therapeutics SA Income Statement — Revenue, Profit & Earnings by Year
Ryvu Therapeutics SA's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | zł62.25 Million | zł77.97 Million | zł46.86 Million | zł38.80 Million | zł11.19 Million |
| Cost of Revenue | zł14.80 Million | zł19.58 Million | zł17.55 Million | zł17.41 Million | zł13.73 Million |
| Gross Profit | zł47.45 Million | zł58.39 Million | zł29.31 Million | zł21.40 Million | zł-2.54 Million |
| Research & Development | — | — | — | zł25.99 Million | zł15.02 Million |
| SG&A | — | — | — | zł5.56 Million | zł4.33 Million |
| Total Operating Expenses | zł159.47 Million | zł180.49 Million | zł130.25 Million | zł93.07 Million | zł75.98 Million |
| Operating Income | zł-97.21 Million | zł-122.10 Million | zł-100.95 Million | zł-78.42 Million | zł-103.78 Million |
| EBITDA | — | zł-96.83 Million | zł-81.04 Million | zł-65.21 Million | zł-65.96 Million |
| EBIT | — | zł-107.33 Million | zł-92.02 Million | zł-78.11 Million | zł-78.52 Million |
| Interest Expense | zł8.80 Million | zł3.81 Million | zł97.00K | zł1.09 Million | zł442.00K |
| Income Before Tax | zł-101.14 Million | zł-111.14 Million | zł-92.11 Million | zł-79.19 Million | zł-78.96 Million |
| Income Tax Expense | — | zł297.00K | — | zł4.59 Million | zł115.95K |
| Net Income | zł-101.23 Million | zł-111.44 Million | zł-92.11 Million | zł-83.78 Million | zł-79.08 Million |
Ryvu Therapeutics SA Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Ryvu Therapeutics SA's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | zł224.44 Million | zł378.78 Million | zł403.20 Million | zł474.98 Million | zł228.81 Million |
| Total Current Assets | zł139.25 Million | zł272.44 Million | zł278.39 Million | zł367.93 Million | zł104.25 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | zł48.07 Million | zł65.86 Million | zł175.73 Million | zł528.00K | zł4.99 Million |
| Net Receivables | zł10.60 Million | zł20.92 Million | zł9.19 Million | zł5.05 Million | zł11.74 Million |
| Inventory | zł1.33 Million | zł1.21 Million | zł2.12 Million | zł1.76 Million | zł1.96 Million |
| Property, Plant & Equipment | — | — | — | — | zł91.18 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | zł170.60 Million | zł234.89 Million | zł143.61 Million | zł131.59 Million | zł59.39 Million |
| Total Current Liabilities | zł61.58 Million | zł107.93 Million | zł69.70 Million | zł44.81 Million | zł36.20 Million |
| Long-term Debt | zł70.27 Million | zł73.33 Million | zł0.00 | zł0.00 | zł742.42K |
| Net Debt | zł14.83 Million | zł-84.56 Million | zł-57.03 Million | zł-99.15 Million | zł-78.17 Million |
| Total Stockholder Equity | zł53.83 Million | zł143.88 Million | zł259.59 Million | zł343.39 Million | zł161.30 Million |
| Retained Earnings | zł-212.67 Million | zł-111.44 Million | zł-10.00K | zł92.10 Million | zł175.88 Million |
Ryvu Therapeutics SA Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Ryvu Therapeutics SA generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | zł-114.10 Million | zł-129.48 Million | zł-84.55 Million | zł21.32 Million | zł-57.87 Million |
| Capital Expenditures | zł7.47 Million | zł5.90 Million | zł8.58 Million | zł9.29 Million | zł11.98 Million |
| Free Cash Flow | zł-121.57 Million | zł-135.38 Million | zł-88.11 Million | zł12.03 Million | zł-69.85 Million |
| Investing Cash Flow | — | zł137.16 Million | zł-195.54 Million | zł690.00K | zł8.06 Million |
| Financing Cash Flow | — | zł94.21 Million | zł240.83 Million | zł-2.46 Million | zł-3.17 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | zł22.18 Million | zł23.00 Million |
| Depreciation | zł11.06 Million | zł10.49 Million | zł10.97 Million | zł12.90 Million | zł12.56 Million |
| Change in Cash | zł-99.99 Million | zł102.13 Million | zł-43.98 Million | zł18.68 Million | zł-52.98 Million |
Ryvu Therapeutics SA Earnings History — EPS Actual vs. Analyst Estimates
Track Ryvu Therapeutics SA's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 31, 2026 | -0.55 | — | — |
| Dec 31, 2025 | -0.76 | — | — |
| Sep 30, 2025 | -1.07 | — | — |
| Jun 30, 2025 | -1.46 | — | — |
| Mar 31, 2025 | -1.09 | — | — |
| Mar 13, 2025 | -1.52 | — | — |
| Nov 07, 2024 | -1.15 | — | — |
| Jun 30, 2024 | -1.32 | — | — |